EUVIMEDEUVIMED entdecken
Open Access

Targeting the heparan sulfate proteoglycan/heparanase axis as a novel therapeutic strategy to drive adipogenesis and block tumor growth of dedifferentiated liposarcoma

Cinzia Lanzi, Enrica Favini, Laura Dal Bo, Monica Tortoreto, Stefano Percio, Valentina Zuco, Gian Paolo Dagrada, Silvia Brich, Paola Collini, Loris De Cecco, Dario Callegaro, Roberta Sanfilippo und 5 weitere

International Journal of Biological Sciences · 2026

DOI: 10.7150/ijbs.133802 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Biological Sciences, 2026. Verfasst von Cinzia Lanzi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Pharmacology, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Hauptthemen laut MEDLINE: Adipogenesis, Liposarcoma, Heparan Sulfate Proteoglycans, Glucuronidase. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdipogenesisLiposarcomaHeparan Sulfate ProteoglycansGlucuronidaseHumansAnimalsMiceHeparanaseCell Line, TumorSyndecan-1Signal TransductionCell Differentiation

Stichwörter der Autor:innen

AKTCX-01adipogenesisc-Metdedifferentiated liposarcomasyndecan-1

Substanzen

Heparan Sulfate ProteoglycansGlucuronidaseHeparanaseSyndecan-1

Autor:innen und Institutionen

  • Molecular Pharmacology, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Pathology Unit 2, Department of Advanced Diagnostics Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Soft Tissue Tumor Pathology Unit, Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Integrated Biology of Rare Tumors, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Medical Oncology 2, Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Förderung

  • Cancer Research UK

Zitieren

APA

Lanzi, C., Favini, E., Dal Bo, L., Tortoreto, M., Percio, S., Zuco, V., Dagrada, G. P., Brich, S., Collini, P., De Cecco, L., Callegaro, D., Sanfilippo, R., Gronchi, A., Zaffaroni, N., Assaraf, Y. G., Pasquali, S., & Cassinelli, G. (2026). Targeting the heparan sulfate proteoglycan/heparanase axis as a novel therapeutic strategy to drive adipogenesis and block tumor growth of dedifferentiated liposarcoma. International Journal of Biological Sciences. https://doi.org/10.7150/ijbs.133802

Vancouver

Lanzi C, Favini E, Dal Bo L, Tortoreto M, Percio S, Zuco V, et al. Targeting the heparan sulfate proteoglycan/heparanase axis as a novel therapeutic strategy to drive adipogenesis and block tumor growth of dedifferentiated liposarcoma. International Journal of Biological Sciences. 2026. doi:10.7150/ijbs.133802

BibTeX
@article{Lanzi2026,
  author = {Lanzi, Cinzia and Favini, Enrica and Dal Bo, Laura and Tortoreto, Monica and Percio, Stefano and Zuco, Valentina and Dagrada, Gian Paolo and Brich, Silvia and Collini, Paola and De Cecco, Loris and Callegaro, Dario and Sanfilippo, Roberta and Gronchi, Alessandro and Zaffaroni, Nadia and Assaraf, Yehuda G and Pasquali, Sandro and Cassinelli, Giuliana},
  title = {Targeting the heparan sulfate proteoglycan/heparanase axis as a novel therapeutic strategy to drive adipogenesis and block tumor growth of dedifferentiated liposarcoma},
  journal = {International Journal of Biological Sciences},
  year = {2026},
  doi = {10.7150/ijbs.133802}
}
Kostenlos starten →